PD50-06 A 17-GENE GENOMIC PROSTATE SCORE AS A PREDICTOR OF ADVERSE PATHOLOGY FOR MEN ON ACTIVE SURVEILLANCE

Introduction and Objective:OncotypeDx Genomic Prostate Score (GPS) test is an RNA expression assay that can be performed on prostate biopsies. We sought to determine whether GPS was associated with increased risk of adverse pathology for men enrolled on active surveillance (AS) who later underwent RP.Methods:All AS patients at the University of California San Francisco (UCSF) were identified who had Gleason score (GS) 3+3 or low volume (≤33% positive cores) GS 3+4 PCa, GPS testing at diagnostic or confirmatory biopsy, clinical stage T1/T2, PSA 0.05 ng/mL following RP.Results:Of 215 men, 83% (N=179) were low risk, and 17% (N=36) were intermediate risk by CAPRA scoring. Median GPS was 26.4 (interquartile range [IQR]: 18.8, 34.6). In multivariate analysis, highe...